Cargando…
Host Interactions with Engineered T-cell Micropharmacies
Genetically engineered, cytotoxic, adoptively transferred T cells localize to antigen-positive cancer cells inside patients, but tumor heterogeneity and multiple immune escape mechanisms have prevented the eradication of most solid tumor types. More effective, multifunctional engineered T cells are...
Autores principales: | Bourne, Christopher M., Wallisch, Patrick, Dacek, Megan M., Gardner, Thomas J., Pierre, Stephanie, Vogt, Kristen, Corless, Broderick C., Bah, Mamadou A., Romero-Pichardo, Jesus E., Charles, Angel, Kurtz, Keifer G., Tan, Derek S., Scheinberg, David A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472090/ https://www.ncbi.nlm.nih.gov/pubmed/37379366 http://dx.doi.org/10.1158/2326-6066.CIR-22-0879 |
Ejemplares similares
-
Host-cell Interactions of Engineered T cell Micropharmacies
por: Bourne, Christopher M., et al.
Publicado: (2023) -
Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery
por: Gardner, Thomas J., et al.
Publicado: (2020) -
Autologous, lentivirus‐modified, T‐rapa cell “micropharmacies” for lysosomal storage disorders
por: Nagree, Murtaza S, et al.
Publicado: (2022) -
CAR Chase: Where Do Engineered Cells Go in Humans?
por: Krebs, Simone, et al.
Publicado: (2020) -
Engineering CAR-T cells for radiohapten capture in imaging and radioimmunotherapy applications
por: Kurtz, Keifer, et al.
Publicado: (2023)